Which cognitive domains are improved by treatment with vortioxetine?
Open accessAbstract
BACKGROUND: These post hoc analyses evaluated vortioxetine efficacy on cognitive dysfunction in depression. Data were from a double-blind, randomized, fixed-dose, placebo-controlled, 8-week depression study in adults aged 18-65 years (n = 602) with DSM-IV-defined major depressive disorder (MDD). Subjects were randomized (1:1:1) to vortioxetine 10mg/day or 20mg/day or placebo. METHODS: Cognitive function was assessed at baseline, Week 1 (10mg/day only) and Week 8 using Digit Symbol Substitution Test (DSST) number of correct symbols, Rey Auditory Verbal Learning Test, Trail Making Test, Stroop test, Simple Reaction Time, and Choice Reaction Time tests. The cognition variables were standardized and used for constructing composite Z-scores for the cognitive domains of executive function, attention/speed of processing, and memory. RESULTS: At Week 1, vortioxetine 10mg/day separated from placebo for attention/speed of processing (standardized composite Z-score = 0.21; p = 0.0238) and DSST number of correct symbols (standardized effect size = 0.18; p = 0.0458) and for executive function (standardized composite Z-score = 0.20; p = 0.0274). At Week 8, vortioxetine 10mg/day and 20mg/day separated from placebo for executive function and attention/speed of processing, with standardized composite Z-scores ranging from 0.35 to 0.49 (all p < 0.01). Standardized composite Z-scores for memory were 0.31 ( p = 0.0036, 10mg/day) and 0.22 ( p = 0.0349, 20mg/day). Standardized effect sizes for DSST were 0.51 ( p < 0.0001, 10mg/day) and 0.52 ( p < 0.0001, 20mg/day). Results are limited by the post hoc nature of the analyses and the absence of an active reference in the original study. CONCLUSIONS: Vortioxetine (10 and 20mg/day) had a multi-domain beneficial effect on cognitive performance, as evidenced by improvements in measures of executive function, attention/speed of processing, and memory. The effect on the DSST may be due to improvements in several cognitive skills.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Robust evidence exists regarding the use of vortioxetine to treat mood-related symptoms of depression and slowed processing speed, and it is the only FDA-cleared psychotropic medication to treat both.
“Robust evidence exists regarding the use of vortioxetine to treat mood-related symptoms of depression and slowed processing speed (Bennabi et al., 2019;Frampton, 2016;Harrison et al., 2016;Mahableshwarkar et al., 2015;McIntyre et al., 2014), and it is the only FDA-cleared psychotropic medication to treat both.”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Harrison et al., 2016
The Results and Discussion report that vortioxetine improved attention and speed of processing in adults with major depressive disorder. The paper does not establish the cited clause’s claim about treating mood-related symptoms specifically. The FDA-cleared assertion follows the citation rather than being directly attributed to it. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Wechsler Adult Intelligence Scale--Third Edition
Wechsler, D. (2019) · PsycTESTS Dataset · doi:10.1037/t49755-000 · Cited by 2,327 · see citing works
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292 · see citing works
The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860 · see citing works
McIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765 · see citing works
A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder
Lee, R. S. C., Hermens, D. F., Porter, M. A., & Redoblado-Hodge, M. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.023 · Cited by 737 · see citing works
Conradi, H. J., Ormel, J., & de Jonge, P. (2011) · Psychological Medicine · doi:10.1017/s0033291710001911 · Cited by 515 · see citing works
Cognitive functioning in major depression – a summary
Hammar, Å. (2009) · Frontiers in Human Neuroscience · doi:10.3389/neuro.09.026.2009 · Cited by 491 · see citing works
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445 · see citing works
Self-citationMcIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433 · see citing works
Self-citationCognitive impairment in the remitted state of unipolar depressive disorder: A systematic review
Hasselbalch, B. J., Knorr, U., & Kessing, L. V. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.11.011 · Cited by 406 · see citing works
McClintock, S. M., Husain, M. M., Greer, T. L., & Cullum, C. M. (2010) · Neuropsychology · doi:10.1037/a0017336 · Cited by 344 · see citing works
Mahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.52 · Cited by 307 · see citing works
Cognitive dysfunction in unipolar depression: Implications for treatment
Trivedi, M. H., & Greer, T. L. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.09.012 · Cited by 294 · see citing works
Neuropsychological Impairment in Major Depression: Its Nature, Origin and Clinical Significance
Porter, R. J., Bourke, C., & Gallagher, P. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670601109881 · Cited by 236 · see citing works
Papakostas, G. I. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08710 · Cited by 153 · see citing works
Basso, M. R., & Bornstein, R. A. (1999) · Neuropsychology · doi:10.1037/0894-4105.13.4.557 · Cited by 141 · see citing works
Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease
Rockwood, K. J. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.029074 · Cited by 134 · see citing works
Basso, M. R., & Bornstein, R. A. (1999) · Neuropsychology · doi:10.1037//0894-4105.13.4.557 · Cited by 128 · see citing works
Baune, B. T., & Renger, L. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.05.013 · Cited by 115 · see citing works
Depression and Cognitive Impairment in Older Adults
Weisenbach, S. L., Boore, L. A., & Kales, H. C. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0278-7 · Cited by 104 · see citing works
A Review of Modern Antidepressants Effects on Neurocognitive Function
Biringer, E., Rongve, A., & Lund, A. (2009) · Current Psychiatry Reviews · doi:10.2174/157340009788971137 · Cited by 73 · see citing works
Ferris, S. H., Lucca, U., Mohs, R. C., Dubois, B., Wesnes, K. A., Erzigkeit, H., Geldmacher, D., & Bodick, N. C. (1997) · PubMed · Cited by 51 · see citing works
Digit symbol coding and general cognitive ability in schizophrenia: worth another look?
Dickinson, D. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.049387 · Cited by 44 · see citing works
Harrison, J., Henderson, L., & Kennard, C. (1995) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.59.5.499 · Cited by 29 · see citing works
Self-citationEvaluating cognitive dysfunction in major depressive disorder
Cha, D. S. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139860567.017 · Cited by 13 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cognitive Impairment Associated with Cancer: A Brief Review.
Pendergrass, J. C., Targum, S. D., & Harrison, J. (2018) · PubMed Central · Cited by 219 · see citing works
Self-citationCognitive dysfunction in major depressive disorder
Knight, M. J., & Baune, B. T. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000378 · Cited by 207 · see citing works
Advances in antidepressants for treating post-stroke depression
Paolucci, S. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1334765 · Cited by 111 · see citing works
Advancing Translational Research Using NIMH Research Domain Criteria and Computational Methods
Sanislow, C. A., Ferrante, M., Pacheco, J. L., Rudorfer, M. V., & Morris, S. E. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.024 · Cited by 93 · see citing works
Vortioxetine for cognitive enhancement in major depression: From animal models to clinical research
Bennabi, D., Haffen, E., & Van Waes, V. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00771 · Cited by 75 · see citing works
“(61) studied which specific domains vortioxetine improves and demonstrated a procognitive effect in vortioxetinetreated patients at 8 weeks, even after correcting for a change in depression severity.”
BackgroundCognitive dysfunction in major depression: From assessment to novel therapies
Atique-Ur-Rehman, H., & Neill, J. C. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.013 · Cited by 72 · see citing works
Salagre, E., Solé, B., Tomioka, Y., Fernandes, B. S., Hidalgo-Mazzei, D., Garriga, M., Jimenez, E., Sanchez-Moreno, J., Vieta, E., & Grande, I. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.034 · Cited by 71 · see citing works
De Diego-Adeliño, J., Crespo, J. M., Mora, F., Neyra, A., Iborra, P., Gutiérrez-Rojas, L., & Salonia, S. F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2019705 · Cited by 67 · see citing works
Cumbo, E., Cumbo, S., Torregrossa, S., & Migliore, D. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.24 · Cited by 57 · see citing works
Chokka, P. R., Bougie, J. K., Proulx, J., Tvistholm, A. H., & Ettrup, A. (2019) · CNS Spectrums · doi:10.1017/s1092852919000786 · Cited by 55 · see citing works
Chokka, P., Bougie, J., Rampakakis, E., & Proulx, J. (2019) · CNS Spectrums · doi:10.1017/s1092852918000913 · Cited by 48 · see citing works
Harrison, J., Barry, H., Baune, B. T., Best, M. W., Bowie, C. R., Cha, D. S., Culpepper, L., Fossati, P., Greer, T. L., Harmer, C. J., et al. (2018) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1736 · Cited by 44 · see citing works
Self-citationEfficacy of vortioxetine on the physical symptoms of major depressive disorder
Christensen, M. C., Florea, I., Lindstén, A., & Baldwin, D. S. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118788826 · Cited by 42 · see citing works
Huang, I.-C., Chang, T.-S., Chen, C., & Sung, J.-Y. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac054 · Cited by 41 · see citing works
Vortioxetina: una nueva alternativa en el trastorno depresivo mayor
Salagre, E., Grande, I., Solé, B., Sánchez‐Moreno, J., & Vieta, E. (2017) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2017.06.006 · Cited by 40 · see citing works
Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain
Zuena, A. R., Maftei, D., Alemà, G., Moro, F. D., Lattanzi, R., Casolini, P., & Nicoletti, F. (2018) · Molecular Pain · doi:10.1177/1744806918808987 · Cited by 37 · see citing works
Therapeutic Potential and Limitation of Serotonin Type 7 Receptor Modulation
Fukuyama, K., Motomura, E., & Okada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032070 · Cited by 33 · see citing works
Rohde, D., Gaynor, E., Large, M., Mellon, L., Bennett, K., Williams, D. J., Brewer, L., Hall, P., Callaly, E. L., Dolan, E., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223997 · Cited by 32 · see citing works
A Kiosk Station for the Assessment of Multiple Cognitive Domains and Cognitive Enrichment of Monkeys
Womelsdorf, T., Thomas, C., Neumann, A. R., Watson, M. R., Boroujeni, K. B., Hassani, S. A., Parker, J. M., & Hoffman, K. L. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.721069 · Cited by 30 · see citing works
Santos‐García, D., Losada, M. G. A., Hernando, I. C., Cabo, I., Baña, R. M. Y., Redondo, R. A., González, J. M. P., Bartolomé, C. C., Painceiras, M. J. F., Alvarado, M. C. Í., et al. (2022) · Brain Sciences · doi:10.3390/brainsci12111466 · Cited by 31 · see citing works
Biederman, J., Lindstén, A., Sluth, L. B., Petersen, M. L., Ettrup, A., Eriksen, H. F., & D, M. F. M. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119832538 · Cited by 30 · see citing works
Vortioxetine: A new alternative for the treatment of major depressive disorder
Salagre, E., Grande, I., Solé, B., Sánchez‐Moreno, J., & Vieta, E. (2018) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2018.02.005 · Cited by 28 · see citing works
Pehrson, A. L., Pedersen, C. S., Tølbøl, K. S., & Sánchez, C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00162 · Cited by 29 · see citing works
Vortioxetine improves cognition in mild cognitive impairment
Tan, S. N., & Tan, C. S. C. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000376 · Cited by 26 · see citing works
Li, Z., Liu, S., Wu, Q., Li, J., Yang, Q., Wang, X., Peng, P., Wang, Q., Liu, Y., Li, M., et al. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad018 · Cited by 26 · see citing works
Vortioxetine administration attenuates cognitive and synaptic deficits in 5×FAD mice
Jiang, L., Huang, G.-D., Feng, S., Wang, H., Zhang, C., & Yu, X. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05452-9 · Cited by 21 · see citing works
Wang, G., Xiao, L., Ren, H., Simonsen, K., Ma, J., Xu, X., Guo, P., Wang, Z., Bai, L., Heldbo Reines, E., et al. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s358253 · Cited by 22 · see citing works
Vortioxetine on Cognition in Schizophrenia
Bruno, A., Zoccali, R. A., Troili, G. M., Scala, L., Pandolfo, G., Cedro, C., Mento, C., Santoro, V., Spina, E., & Muscatello, M. R. A. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001242 · Cited by 19 · see citing works
Effects of Vortioxetine on depression model rats and expression of BDNF and Trk B in hippocampus
Sun, B., Lv, Y., Xu, H., Qi, C., Li, C., & Liu, P. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9026 · Cited by 19 · see citing works
Hemispheric stroke: Mood disorders
Harciarek, M., & Mańkowska, A. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-822290-4.00007-4 · Cited by 18 · see citing works
Cognition and violent behavior in psychotic disorders: A nationwide case-control study
Lamsma, J., Cahn, W., & Fazel, S. (2019) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2019.100166 · Cited by 15 · see citing works
O'Regan, D. J., Poole, N. A., Otaiku, A. I., Jackson, M. L., & Rosenzweig, I. (2025) · Current Treatment Options in Neurology · doi:10.1007/s11940-025-00847-5 · Cited by 12 · see citing works
Cuomo, A., Aguglia, A., Berardis, D. D., Ventriglio, A., Gesi, C., & Fagiolini, A. M. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00505-1 · Cited by 13 · see citing works
Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
Harrison, J. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0386-7 · Cited by 12 · see citing works
Self-citationCommentary: Composite cognitive and functional measures for early stage Alzheimer's disease trials
Harrison, J. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12009 · Cited by 9 · see citing works
Self-citationBerardelli, I., Rogante, E., Formica, F., Iannazzo, R., mammoliti, A. V., Riccioni, R., Veizi, S., McIntyre, R. S., & Pompili, M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811241309612 · Cited by 7 · see citing works
Cognitive Dysfunction in Major Depressive Disorder: Cause and Effect
Knight, M. J., Aboustate, N., & Baune, B. T. (2018) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-018-0160-y · Cited by 8 · see citing works
McIntyre, R. S., Lipsitz, O., Rodrigues, N. B., Subramaniapillai, M., Nasri, F., Lee, Y., Fehnert, B., King, J., Chrones, L., Kratiuk, K., et al. (2022) · JMIR Mental Health · doi:10.2196/33871 · Cited by 7 · see citing works
Screening and measurement of cognitive impairment in psychiatry
Harrison, J. (2019) · CNS Spectrums · doi:10.1017/s1092852918001657 · Cited by 7 · see citing works
Self-citationMattingly, G. W., Brunner, E., Chrones, L., Lawrence, D. F. E., Simonsen, K., & Ren, H. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.977560 · Cited by 7 · see citing works
Lamsma, J., Harte, J. M., & Cahn, W. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.10.008 · Cited by 5 · see citing works
Impact of sleep disturbance in shift workers on hippocampal volume and psychomotor speed
Song, Y., Kim, S., Joo, Y., Ha, E., Shim, Y., Lee, H., Jeong, H. S., Lyoo, I. K., Yoon, S. J., & Lee, S. L. (2024) · SLEEP · doi:10.1093/sleep/zsae100 · Cited by 6 · see citing works
Szmyd, J., Lewczuk, K., Teopiz, K. M., McIntyre, R. S., & Wichniak, A. (2023) · Brain Sciences · doi:10.3390/brainsci13030389 · Cited by 5 · see citing works
Harrison, J., & Hendrix, S. B. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00021-7 · Cited by 5 · see citing works
Self-citationParsing the heterogeneity of depression: a data-driven subgroup derived from cognitive function
Xu, C., Tao, Y., Lin, Y., Zhu, J., Li, Z., Li, J., Wang, M., Huang, T., & Shi, C. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1537331 · Cited by 4 · see citing works
Managing interactions between cognitive enhancers and other psychotropics
Tang, S. W., Tang, W. H., & Leonard, B. E. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000172 · Cited by 4 · see citing works
Subhas, N., Ang, J. K., Tan, K., & Ahmad, S. N. A. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2149415 · Cited by 4 · see citing works
Cumbo, E., & Migliore, D. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251340084 · Cited by 3 · see citing works
Hutnyan, M., & McClintock, S. M. (2025) · Transcranial Magnetic Stimulation · doi:10.1016/j.transm.2025.100088 · Cited by 2 · see citing works
Cuomo, A., Barillà, G., Cattolico, M., Pardossi, S., Mariantoni, E., Koukouna, D., Carmellini, P., & Fagiolini, A. M. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2333394 · Cited by 2 · see citing works
Rolan, P. E., Seckl, J. R., Taylor, J. A., Harrison, J., Maruff, P. T., Woodward, M., Mills, R., Jaros, M. J., & Hilt, D. C. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1496 · Cited by 2 · see citing works
Self-citationMurthy, N. V., Xu, R., Zhong, W., & Harvey, P. D. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.025 · Cited by 2 · see citing works
Reznik, A. M., Syunyakov, T., Mudrak, A. V., Zakharov, N. B., Popova, Z. B., Khoroshilova, A. N., Ig, K., Sayfulina, A. M., Eliseenko, A. M., Matvievskaya, T. K., et al. (2023) · Consortium Psychiatricum · doi:10.17816/cp3728 · Cited by 2 · see citing works
Palva, J. M., Juvonen, J. J., Lukka, L., Vesterinen, M., Salonen, A., Bergman, V.-R., Partanen, P., Pohjola, L., Kolehmainen, J., Meimer, M., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5409098 · Cited by 2 · see citing works
The Use and Development of Clinical Measures of Alzheimer’s Disease Trials
Harrison, J. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.025 · Cited by 1 · see citing works
Self-citationTranslational Approaches for Antidepressant Drug Development
Marek, G. J. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00007-2 · Cited by 1 · see citing works
Risk factors for violent behavior in people with psychotic disorders
Lamsma, J. (2021) · doi:10.33540/496 · Cited by 1 · see citing works
Desfossés, C. Y., & Blier, P. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as16
Klöbl, M., Matev, V., Stöhrmann, P., Dörl, G., Rothenberg, M., Donath, J., Cukaci, C., Barede, K. A., Lanzenberger, R. R., Pjrek, E., et al. (2025) · medRxiv · doi:10.64898/2025.12.10.25341891
- Authors
- Harrison, J. E., Lophaven, S., & Olsen, C. K.
- Affiliations
- Lundbeck (Denmark) (DK)
- Corresponding author
- Harrison, John E
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-05-26
- Volume
- 19
- Issue
- 10
- Pages
- pyw054
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC5091828
- OpenAlex
- W2403465849
- Cited by
- 59
- References
- 24
- Citations by year
- 2025: 8 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 5 · 2020: 4 · 2019: 12 · 2018: 9 · 2017: 5
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- vortioxetine, major depressive disorder, cognitive impairment, executive function, memory, Digit Symbol Substitution Test, Rey Auditory Verbal Learning Test, Trail Making Test, Stroop task
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
